University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Feature: Biorepository and Tissue Biomarker Technology (BTBMT) Core

Feature: Biorepository and Tissue Biomarker Technology (BTBMT) Core

March 13, 2019

The goal of the Biorepository and Tissue Biomarker Technology Shared Resource (BTBMT) is to provide the infrastructure to support the life cycle and QA/QC of high quality biospecimens for cancer research. The multifaceted life cycle includes patient consenting, biospecimen acquisition, processing, storage, and distribution. The ...
Highlights from the Precision Medicine World Conference 2019

Highlights from the Precision Medicine World Conference 2019

March 1, 2019

For the fourth year, UCSF co-hosted the Precision Medicine World Conference, which attracted attendees from 35 countries to hear about the growing prominence of data science, artificial intelligence, and deep learning that is creating a sea change in nearly every aspect of health care and biomedical ...
UCSF's novel approach to a therapeutic cancer vaccine may provide a new option for patients relapsing with AML

UCSF's novel approach to a therapeutic cancer vaccine may provide a new option for patients relapsing with AML

February 11, 2019

An experimental cancer vaccine in early-stage development at the University of California San Francisco has sparked hope that patients with acute myeloid leukemia (AML), an aggressive cancer of the blood, could one day have a life-saving alternative, especially those prone to relapse or unable to ...
Q & A with Thea Tlsty, PhD, on Leading International Team to Study Inflammation and Cancer

Q & A with Thea Tlsty, PhD, on Leading International Team to Study Inflammation and Cancer

January 29, 2019

Thea D. Tlsty, PhD, Professor of Pathology and a UCSF leader in cell cycling and signaling, received a $26 million Grand Challenge Grant from Cancer Research UK (CRUK) to lead an international team exploring how chronic inflammation causes cancer.